
Hugo E Vargas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6129334/publications.pdf Version: 2024-02-01



HUCO E VARCAS

#	Article	IF	CITATIONS
1	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, 149, 649-659.	1.3	725
2	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492.	5.8	509
3	An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. New England Journal of Medicine, 2014, 371, 2375-2382.	27.0	377
4	Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. New England Journal of Medicine, 2018, 378, 354-369.	27.0	361
5	Search for Hepatitis C Virus Negative-Strand RNA Sequences and Analysis of Viral Sequences in the Central Nervous System: Evidence of Replication. Journal of Virology, 2002, 76, 600-608.	3.4	256
6	Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transplantation, 2010, 16, 1373-1378.	2.4	238
7	Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplantation, 2004, 10, 36-41.	2.4	231
8	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology, 2016, 150, 1579-1589.e2.	1.3	225
9	NACSELD acuteâ€onâ€chronic liver failure (NACSELDâ€ACLF) score predicts 30â€day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67, 2367-2374.	7.3	197
10	Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1. Transplantation, 2004, 77, 190-194.	1.0	170
11	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology, 2015, 61, 1880-1886.	7.3	166
12	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology, 2016, 150, 419-429.	1.3	166
13	Outcome of liver transplantation in hepatitis C virus–infected patients who received hepatitis C virus–infected grafts. Gastroenterology, 1999, 117, 149-153.	1.3	162
14	Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: Specific detection of negative-strand viral rna in various tissues. Hepatology, 1998, 28, 1398-1401.	7.3	155
15	Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology, 2008, 47, 1595-1603.	7.3	147
16	Detection and Analysis of Hepatitis C Virus Sequences in Cerebrospinal Fluid. Journal of Virology, 2002, 76, 10064-10068.	3.4	145
17	Endoscopic treatment of anastomotic biliary strictures after deceased donor liver transplantation: outcomes after maximal stent therapy. Gastrointestinal Endoscopy, 2007, 66, 44-51.	1.0	145
18	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. Journal of Hepatology, 2014, 61, 1238-1246.	3.7	126

#	Article	IF	CITATIONS
19	Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study. American Journal of Transplantation, 2014, 14, 1817-1827.	4.7	121
20	Portal Vein Thrombosis in Patients with End Stage Liver Disease Awaiting Liver Transplantation: Outcome of Anticoagulation. Digestive Diseases and Sciences, 2013, 58, 1776-1780.	2.3	115
21	Relationship between sarcopenia, sixâ€minute walk distance and healthâ€related quality of life in liver transplant candidates. Clinical Transplantation, 2015, 29, 134-141.	1.6	107
22	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. Clinical Gastroenterology and Hepatology, 2017, 15, 565-574.e4.	4.4	105
23	Endoscopic treatment of anastomotic biliary strictures after living donor liver transplantation: outcomes after maximal stent therapy. Gastrointestinal Endoscopy, 2013, 77, 47-54.	1.0	103
24	Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transplantation, 2013, 19, 690-700.	2.4	99
25	Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. Liver Transplantation, 2008, 14, 886-892.	2.4	98
26	Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the <scp>OT</scp> â€0401 and <scp>REVERSE</scp> randomised clinical studies. Alimentary Pharmacology and Therapeutics, 2017, 45, 1390-1402.	3.7	90
27	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 756-765.e3.	4.4	89
28	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. American Journal of Gastroenterology, 2018, 113, 556-563.	0.4	87
29	Acuteâ€onâ€Chronic Liver Failure: Getting Ready for Prime Time?. Hepatology, 2018, 68, 1621-1632.	7.3	86
30	Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation, 2009, 15, 1872-1881.	2.4	85
31	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. Mayo Clinic Proceedings, 2020, 95, 2382-2394.	3.0	77
32	The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transplantation, 1998, 4, 22-27.	1.8	75
33	Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage. Journal of Clinical Gastroenterology, 2017, 51, 446-453.	2.2	72
34	The Presence of Active Hepatitis C Virus Replication in Lymphoid Tissue in Patients Coinfected with Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 1998, 178, 1189-1192.	4.0	69
35	Detection of Hepatitis G Virus Replication Sites by Using Highly Strand-Specific Tth-Based Reverse Transcriptase PCR. Journal of Virology, 1998, 72, 3072-3075.	3.4	66
36	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology, 2020, 159, 1715-1730.e12.	1.3	65

#	Article	IF	CITATIONS
37	Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation, 2003, 76, 1487-1491.	1.0	64
38	Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transplantation, 2002, 8, 1014-1019.	2.4	59
39	Hepatic Steatosis in Hepatitis C Virus Genotype 3 Infection: Does It Correlate with Body Mass Index, Fibrosis, and HCV Risk Factors?. Digestive Diseases and Sciences, 2004, 49, 25-29.	2.3	58
40	Exposure of Hepatitis C Virus (HCV) RNA-Positive Recipients to HCV RNA-Positive Blood Donors Results in Rapid Predominance of a Single Donor Strain and Exclusion and/or Suppression of the Recipient Strain. Journal of Virology, 2001, 75, 2059-2066.	3.4	55
41	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transplantation, 2019, 25, 870-880.	2.4	55
42	Living donor liver transplantation for hepatitis C-related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transplantation, 2006, 12, 560-565.	2.4	54
43	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology, 2015, 62, 1004-1012.	7.3	54
44	Outcomes After Listing for Liver Transplant in Patients With Acuteâ€onâ€Chronic Liver Failure: The Multicenter North American Consortium for the Study of Endâ€Stage Liver Disease Experience. Liver Transplantation, 2019, 25, 571-579.	2.4	53
45	Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis1. Transplantation, 2002, 73, 1598-1602.	1.0	51
46	Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transplantation, 2005, 11, 479-489.	2.4	49
47	DETECTION OF HEPATITIS C VIRUS REPLICATION IN PERIPHERAL BLOOD MONONUCLEAR CELLS AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 66, 664-666.	1.0	48
48	Nonsteroidal Anti-Inflammatory Drug–Induced Hepatoxicity. Clinics in Liver Disease, 2013, 17, 643-656.	2.1	47
49	Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2020, 18, 3008-3016.e2.	4.4	46
50	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1339.	0.4	44
51	Hepatitis C Virus Quasiâ€ S pecies Dynamics Predict Progression of Fibrosis after Liver Transplantation. Journal of Infectious Diseases, 2004, 189, 2037-2046.	4.0	42
52	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1091-1100.	0.4	41
53	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multiâ€centre cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1518-1527.	3.7	40
54	Regional Variations in Peer Reviewed Liver Allocation Under the MELD System. American Journal of Transplantation, 2005, 5, 2244-2247.	4.7	38

#	Article	IF	CITATIONS
55	Hepatitis C: Magnitude of the problem. Liver Transplantation, 2002, 8, S3-S6.	2.4	36
56	Transient left ventricular apical ballooning syndrome (Takotsubo cardiomyopathy) following orthotopic liver transplantation. Liver Transplantation, 2007, 13, 1343-1345.	2.4	36
57	The use of hepatitis C-infected grafts in liver transplantation. Liver Transplantation, 2003, 9, S48-S51.	2.4	35
58	New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. Journal of Transplantation, 2013, 2013, 1-7.	0.5	34
59	Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with endâ€stage liver disease and normal serum creatinine awaiting liver transplantation. Clinical Transplantation, 2014, 28, 579-584.	1.6	32
60	Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. Digestive Diseases and Sciences, 2004, 49, 38-41.	2.3	31
61	Vitamin A toxicity: When one a day doesn't keep the doctor away. Liver Transplantation, 2006, 12, 1888-1891.	2.4	30
62	A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002. Liver Transplantation, 2002, 8, 2-9.	2.4	29
63	Treatment of hepatitis C in liver transplant recipients. Liver Transplantation, 2009, 15, 126-135.	2.4	29
64	Hepatitis G Virus Infection in American Patients with Cryptogenic Cirrhosis: No Evidence for Liver Replication. Journal of Infectious Diseases, 1997, 176, 1491-1495.	4.0	27
65	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. Hepatology, 2021, 74, 2699-2713.	7.3	27
66	Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transplantation, 2003, 9, 1129-1144.	2.4	26
67	Inpatient Admissions for Drug-induced Liver Injury: Results from a Single Center. Digestive Diseases and Sciences, 2008, 53, 1977-1982.	2.3	26
68	Liver Transplantation: From Child to MELD. Medical Clinics of North America, 2009, 93, 931-950.	2.5	26
69	Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation. Journal of Transplantation, 2012, 2012, 1-6.	0.5	26
70	Distribution of Infecting Hepatitis C Virus Genotypes in End-Stage Liver Disease Patients at a Large American Transplantation Center. Journal of Infectious Diseases, 1997, 175, 448-450.	4.0	24
71	MANAGEMENT OF PORTAL HYPERTENSION–RELATED BLEEDING. Surgical Clinics of North America, 1999, 79, 1-22.	1.5	24
72	Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?. Digestive Diseases and Sciences, 2007, 52, 732-736.	2.3	23

#	Article	IF	CITATIONS
73	Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: Effect of viral hepatitis D. Liver Transplantation, 2000, 6, 92-96.	2.4	22
74	Hepatic B-cell non-Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transplantation, 2005, 11, 796-799.	2.4	20
75	Persistence of Hepatitis C Virus in Peripheral Blood Mononuclear Cells of Sustained Viral Responders to Pegylated Interferon and Ribavirin Therapy. Digestive Diseases and Sciences, 2008, 53, 2564-2568.	2.3	20
76	Severe Hepatotoxicity Caused by a Methasteron-containing Performance-enhancing Supplement. Journal of Clinical Gastroenterology, 2009, 43, 287.	2.2	20
77	Clinical significance of elevated alpha-fetoprotein in adults and children. Digestive Diseases and Sciences, 2001, 46, 1709-1713.	2.3	19
78	Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clinical Gastroenterology and Hepatology, 2004, 2, 183-197.	4.4	19
79	Artificial Neural Network and Tissue Genotyping of Hepatocellular Carcinoma in Liver-Transplant Recipients: Prediction of Recurrence. Transplantation, 2005, 79, 1737-1740.	1.0	19
80	Peginterferon-α-2b and Ribavirin for Hepatitis C Recurrence Postorthotopic Liver Transplantation. Journal of Clinical Gastroenterology, 2012, 46, 700-708.	2.2	18
81	Docetaxel Induced Sclerosing Cholangitis. Digestive Diseases and Sciences, 2015, 60, 3814-3816.	2.3	18
82	Association between Hepatitis B Virus Core Promoter Rearrangements and Hepatocellular Carcinoma. Biochemical and Biophysical Research Communications, 1998, 244, 812-814.	2.1	17
83	Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single-center experience. Liver Transplantation, 2004, 10, 529-533.	2.4	17
84	Living donor liver transplantation in polycystic liver disease. Liver Transplantation, 2008, 14, 680-683.	2.4	17
85	The Gastroenterologist's Guide to Management of the Post-Liver Transplant Patient. American Journal of Gastroenterology, 2018, 113, 819-828.	0.4	17
86	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2019, 114, 599-606.	0.4	17
87	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. Digestive Diseases and Sciences, 2020, 65, 2571-2579.	2.3	17
88	Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study. American Journal of Transplantation, 2018, 18, 2559-2565.	4.7	16
89	Solid Organ Transplantation From SARS-CoV-2–infected Donors to Uninfected Recipients: A Single-center Experience. Transplantation Direct, 2022, 8, e1286.	1.6	16
90	Liver Transplantation in the MELD Era: A Single-Center Experience. Digestive Diseases and Sciences, 2006, 51, 1070-1078.	2.3	15

#	Article	IF	CITATIONS
91	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. Digestive Diseases and Sciences, 2021, 66, 3612-3618.	2.3	15
92	HEPATITIS G VIRUS COINFECTION IN HEPATITIS C VIRUS-INFECTED LIVER TRANSPLANT RECIPIENTS1. Transplantation, 1997, 64, 786-788.	1.0	15
93	CHANGES IN HEPATITIS C VIRUS POPULATION IN SERUM AND PERIPHERAL BLOOD MONONUCLEAR CELLS IN CHRONICALLY INFECTED PATIENTS RECEIVING LIVER GRAFT FROM INFECTED DONORS. Transplantation, 2001, 72, 833-838.	1.0	15
94	New Therapies for Hepatitis C Virus Infection. Gastroenterology and Hepatology, 2017, 13, 22-31.	0.1	15
95	Macro-Aspartate Aminotransferase and Monoclonal Gammopathy: A Review of Two Cases. Digestive Diseases and Sciences, 2007, 52, 1197-1198.	2.3	14
96	Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience. Transplantation, 2010, 90, 407-411.	1.0	14
97	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2021, 19, 1661-1669.e2.	4.4	14
98	Clinical and Virologic Outcomes of Hepatitis B and C Viral Coinfection After Liver Transplantation: Effect of Viral Hepatitis D. Liver Transplantation, 2000, 6, 92-96.	2.4	13
99	Portal Hypertension Due to a Splenic Arteriovenous Fistula: A Case Report. Digestive Diseases and Sciences, 2006, 51, 1113-1116.	2.3	13
100	Benefits of Direct-Acting Antivirals for Hepatitis C. Annals of Internal Medicine, 2017, 167, 812.	3.9	13
101	Clinical Outcomes of Portosystemic Shunts on the Outcome of Liver Transplantation. Liver Transplantation, 2020, 26, 693-701.	2.4	13
102	Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Abdominal Imaging, 2015, 40, 795-802.	2.0	12
103	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clinical Infectious Diseases, 2017, 65, 1773-1775.	5.8	11
104	Lack of evidence for GB virus C/hepatitis G virus replication in peripheral blood mononuclear cells. Journal of Hepatology, 1998, 28, 179-183.	3.7	10
105	Short-Term Cardiac and Noncardiac Mortality Following Liver Transplantation. Journal of Transplantation, 2010, 2010, 1-7.	0.5	10
106	Amplification and fusion of long fragments of hepatitis C virus genome. Journal of Virological Methods, 1997, 68, 217-223.	2.1	9
107	Virologically compromised donor grafts in liver transplantation. Journal of Hepatology, 2004, 41, 512-521.	3.7	9
108	Natural history of hepatitis C and outcomes following liver transplantation. Minerva Gastroenterologica E Dietologica, 2004, 50, 51-9.	2.2	9

#	Article	IF	CITATIONS
109	Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation. Transplantation, 2004, 78, 580-583.	1.0	8
110	Hydroxycut-related Vanishing Bile DuctÂSyndrome. Clinical Gastroenterology and Hepatology, 2017, 15, 142-144.	4.4	8
111	CASE REPORT: Primary Biliary Cirrhosis and Systemic Amyloidosis, a New Association. Digestive Diseases and Sciences, 2004, 49, 1196-1200.	2.3	7
112	Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterology Clinics of North America, 2004, 33, 549-562.	2.2	7
113	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 565-572.e5.	4.4	7
114	New frontiers in small-bowel imaging: the expanding technology of capsule endoscopy and its impact in clinical gastroenterology. Reviews in Gastroenterological Disorders, 2008, 8, 1-14.	0.6	7
115	Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. Clinical Gastroenterology and Hepatology, 2023, 21, 1031-1040.e3.	4.4	7
116	Hepatitis C virus quasispecies: Misunderstood and mistreated?. Liver Transplantation, 2003, 9, 1048-1052.	2.4	6
117	Selection of different 5' untranslated region hepatitis C virus variants during post-transfusion and post-transplantation infection. Journal of Viral Hepatitis, 2006, 13, 489-498.	2.0	6
118	A difficult case of primary sclerosing cholangitis. Liver Transplantation, 2006, 12, S65-S67.	2.4	6
119	An unusual occurrence of giant cell hepatitis. Liver Transplantation, 2009, 15, 1888-1890.	2.4	6
120	Increased access to liver transplantation for patients with acute on chronic liver failure after implementation of Share 35 Rule: An analysis from the UNOS database. Annals of Hepatology, 2021, 23, 100288.	1.5	6
121	Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft. Cancer Immunology, Immunotherapy, 1992, 35, 151-157.	4.2	5
122	Should Antihepatitis B Virus Core Positive or Antihepatitis C Virus Core Positive Subjects Be Accepted as Organ Donors for Liver Transplantation?. Journal of Clinical Gastroenterology, 2007, 41, 66-74.	2.2	5
123	Portal vein thrombosis. Current Treatment Options in Gastroenterology, 2007, 10, 435-443.	0.8	5
124	HEPATITIS C VIRUS IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM A CHRONICALLY INFECTED PATIENT RECEIVING LIVER GRAFT FROM INFECTED DONOR. Transplantation, 1999, 67, 627-629.	1.0	5
125	Liver Transplantation for Variceal Hemorrhage. Gastrointestinal Endoscopy Clinics of North America, 1999, 9, 347-353.	1.4	4
126	Liver Transplant Case Report: Transgenderism and Liver Transplantation. International Journal of Transgenderism, 2011, 13, 45-49.	3.5	4

#	Article	IF	CITATIONS
127	Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients. Current Opinion in Organ Transplantation, 2015, 20, 259-266.	1.6	4
128	Gastrointestinal endoscopy in the cirrhotic patient. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1005-1013.	3.0	4
129	Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Annals of Hepatology, 2018, 17, 815-821.	1.5	4
130	Hepatic Steatosis Resulting From LMNA-Associated Familial Lipodystrophy. ACG Case Reports Journal, 2020, 7, e00375.	0.4	4
131	Hepatitis C Treatment in 2016: Reasons to Be an OPTIMIST. Hepatology, 2016, 64, 330-332.	7.3	3
132	Comments on cochrane review on directâ€acting antivirals for hepatitis C. Hepatology, 2017, 66, 1016-1019.	7.3	3
133	Risk of Recurrence and 10-Year Outcomes in Surgically Treated Nonmelanoma Skin Cancer in Cardiac and Liver Transplant Recipients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 366-370.	1.3	3
134	The use of virologically compromised organs in liver transplantation. Clinics in Liver Disease, 2003, 7, 573-584.	2.1	2
135	The transplantation candidate with alcohol misuse: The selection minefield. Liver Transplantation, 2008, 14, 1559-1560.	2.4	2
136	Care of the patient with cirrhosis. Clinical Liver Disease, 2015, 5, 100-104.	2.1	2
137	Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International, 2022, , .	3.9	2
138	The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host. Liver Transplantation, 2003, 7, 279-281.	2.4	1
139	Erythropoietin Does Not Increase the Frequency of Thromboembolic Events or Hepatocellular Carcinoma in Hepatitis C Patients Treated With Combination Antiviral Therapy. American Journal of Gastroenterology, 2008, 103, 2161-2162.	0.4	1
140	Colonoscopy in liver disease. Clinical Liver Disease, 2014, 4, 109-112.	2.1	1
141	Prospective Analysis of Metabolic Parameters in the Detection of Diabetes and Metabolic Syndrome in Liver Transplant Recipients. Metabolic Syndrome and Related Disorders, 2016, 14, 305-310.	1.3	1
142	Hepatitis C Virus: No Longer a Barrier to Oncology Care. American Journal of Gastroenterology, 2019, 114, 207-208.	0.4	1
143	Monitoring and Care of the Patient Before Liver Transplantation. , 2005, , 473-489.		1
144	Liver transplantation for variceal hemorrhage. Gastrointestinal Endoscopy Clinics of North America, 1999, 9, 347-53.	1.4	1

#	Article	IF	CITATIONS
145	Hepatitis C for half a century. Gastroenterology, 2000, 119, 1405-1407.	1.3	Ο
146	Impact of hepatitis B and hepatitis C on solid organ transplantation. Current Opinion in Organ Transplantation, 2002, 7, 325-331.	1.6	0
147	Recurrent hepatitis C virus after liver transplantation. Current Opinion in Organ Transplantation, 2004, 9, 99-103.	1.6	Ο
148	Monitoring and Care. , 2014, , 478-493.		0
149	Hepatitis C-Positive Organs for Liver and Kidney Transplantation—Emerging Data and Current Management Strategies. Current Hepatology Reports, 2019, 18, 228-232.	0.9	0
150	Reply. Liver Transplantation, 2021, 27, 146-146.	2.4	0